Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Glicksman

Showing results (401-410 of 411) with videos related to

Pageof 42
Sort By:
Plos Biology|August 6, 2014
Inhibitor of the tyrosine phosphatase STEP reverses cognitive deficits in a mouse model of Alzheimer's diseaseJian Xu, Manavi Chatterjee, Tyler D Baguley, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|June 20, 2019
Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss - results of an exploratory studyIjeoma M Muo, Sandra D MacDonald, Ritu Madan, et al.
European Urology|March 9, 2021
Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis HypothesisRachel M Glicksman, Ur Metser, Douglass Vines, et al.
Science (New York, N.Y.)|September 2, 2017
β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's diseaseShuchi Mittal, Kjetil Bjørnevik, Doo Soon Im, et al.
JAMA Oncology|January 3, 2020
Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A ReviewRachel M Glicksman, Michael C Tjong, Wellington F P Neves-Junior, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 14, 2021
Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyondTing Martin Ma, Soumyajit Roy, Xue Wu, et al.
The Journal of Urology|August 29, 2018
International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone TherapyAlejandro Berlin, Fabio Y Moraes, Noelia Sanmamed, et al.
American Journal of Medical Genetics|April 20, 1999
Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study--preliminary dataD J Allingham-Hawkins, R Babul-Hirji, D Chitayat, et al.
Physics in Medicine and Biology|June 6, 2025
Roadmap: medical physics technologies in brachytherapyWilliam Y Song, Michael Roumeliotis, Junghoon Lee, et al.
BMC Palliative Care|September 7, 2024
A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocolDavid A Palma, Meredith E Giuliani, Rohann J M Correa, et al.
Pageof 42

Showing results (401-410 of 411) with videos related to

Sort By:
Pageof 42
Plos Biology|August 6, 2014
Inhibitor of the tyrosine phosphatase STEP reverses cognitive deficits in a mouse model of Alzheimer's diseaseJian Xu, Manavi Chatterjee, Tyler D Baguley, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|June 20, 2019
Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss - results of an exploratory studyIjeoma M Muo, Sandra D MacDonald, Ritu Madan, et al.
European Urology|March 9, 2021
Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis HypothesisRachel M Glicksman, Ur Metser, Douglass Vines, et al.
Science (New York, N.Y.)|September 2, 2017
β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's diseaseShuchi Mittal, Kjetil Bjørnevik, Doo Soon Im, et al.
JAMA Oncology|January 3, 2020
Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A ReviewRachel M Glicksman, Michael C Tjong, Wellington F P Neves-Junior, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 14, 2021
Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyondTing Martin Ma, Soumyajit Roy, Xue Wu, et al.
The Journal of Urology|August 29, 2018
International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone TherapyAlejandro Berlin, Fabio Y Moraes, Noelia Sanmamed, et al.
American Journal of Medical Genetics|April 20, 1999
Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study--preliminary dataD J Allingham-Hawkins, R Babul-Hirji, D Chitayat, et al.
Physics in Medicine and Biology|June 6, 2025
Roadmap: medical physics technologies in brachytherapyWilliam Y Song, Michael Roumeliotis, Junghoon Lee, et al.
BMC Palliative Care|September 7, 2024
A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocolDavid A Palma, Meredith E Giuliani, Rohann J M Correa, et al.
Pageof 42